Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
Athira's phase 2/3 Alzheimer's trial falls short, sinking stock
Fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up Athira’s stock price.
Nick Paul Taylor
Sep 4, 2024 6:52am
Siemens Healthineers buys Novartis' EU radiodiagnostic network
Aug 26, 2024 11:30am
Actinogen's cortisol blocker fails phase 2 depression study
Aug 12, 2024 10:05am
Lilly faces phase 2 failure of tau-targeting med
Aug 8, 2024 10:48am
Genentech offers Sangamo $2B+ biobucks in neuro licensing deal
Aug 6, 2024 8:05am
Biogen walks away from Denali Alzheimer's collab
Aug 1, 2024 10:27am
